HHS Public Access

Author manuscript

Med. Author manuscript; available in PMC 2025 July 12.

Published in final edited form as:

Med. 2024 July 12; 5(7): 816–825.e4. doi:10.1016/j.medj.2024.03.022.

Normal or improved cardiovascular risk factors in IGF-I deficient adults with growth hormone receptor deficiency

Jaime Guevara-Aguirre[1,2,3,10,11], **Amrendra Mishra**[4,9,10], **Marco Canepa**[5,6], **Carolina Guevara**[1,2], **Álvaro Villacres**[1], **Alexandra Guevara**[2], **Gabriela Peña**[1], **Daniela Lescano**[1], **John Kopchick**[7], **Priya Balasubramanian**[4], **Valter D. Longo**[4,8,11,12]

[1]College of Medicine, Universidad San Francisco de Quito

[2]Instituto de Endocrinología IEMYR

[3]Maastricht University, The Netherlands

[4]Longevity Institute, Davis School of Gerontology and Department of Biological Sciences, University of Southern California, Los Angeles, United States

[5]Cardiovascular Unit, Ospedale Policlinico San Martino IRCCS, Genova, Italy

[6]Department of Internal Medicine and Medical Specialities, University of Genova, Genova, Italy

[7]Department of Biomedical Sciences, Heritage College of Osteopathic Medicine and Edison Biotechnology Institute, Ohio University, Athens, OH, United States

[8]IFOM, AIRC Institute of Molecular Oncology, Milan, Italy

[9]Department of Life Sciences, GITAM (Deemed to be University), Bengaluru, India

Summary

Background: Human subjects with generalized growth hormone (GH) insensitivity due to growth hormone receptor deficiency (GHRD)/Laron syndrome (LS), display a very low incidence of insulin resistance, diabetes, cancer, as well as delayed age-related cognitive decline. However,

[11]Corresponding authors. [12]Lead Contact: Valter D. Longo (vlongo@usc.edu).
[10]These authors contributed equally.

Author contributions

V.D.L., J.G.A., and P.B. designed the study. J.G.A., V.D.L., P.B., supervised the study. J.G.A., C.G., A.V., A.G., G.P., and D.L., contributed to patient recruitment and supervision. J.G.A., M.C., C.G., A.V., A.G., G.P., and D.L contributed to data collection. A.M., M.C., P.B., performed data analysis and prepared tables and figures. A.M. and M.C. performed statistical analyses. A.M. and V.D.L. had unrestricted access to all data. A.M., M.C., J.G.A., and V.D.L., wrote the paper. J.K., contributed to the interpretation, review and editing of the manuscript. All authors read and approved the final article and take responsibility for its content.

Study approval

The study was approved by the Institutional Review Board at the University of Southern California, Los Angeles, USA (HS-14-00127 CR002), and Ethics Committee of the Institute IEMYR, Quito, Ecuador. All participants provided written informed consent.

Declaration of interest

V.D.L. has equity interest in L-Nutra, which develops and sells medical food for the prevention and treatment of diseases. Other authors declare that they have no competing interests.

the risk of cardiovascular (CV) disease in these subjects is poorly understood. Here, we have assessed cardiovascular function, damage, and risk factors in GHRD subjects and their relatives.

Methods: We measured markers of CVD in two phases: one in a cohort of 30 individuals (GHRD=16, control relatives =14), brought to USC, in Los Angeles, and one in a cohort including additional individuals examined in Ecuador (where the subjects live) for a total of 44 individuals (GHRD=21, control relatives =23). Data was collected on GHRD and control groups living in similar geographical locations, and sharing comparable environmental and socioeconomic circumstances.

Results: Compared to controls, GHRD subjects displayed lower serum glucose, insulin, blood pressure, smaller cardiac dimensions, similar pulse wave velocity (PWV), lower carotid artery intima-media thickness (CIMT), lower creatinine and a non-significant but major reduction in the portion of subjects with carotid atherosclerotic plaques (7% GHRDs vs. 36% Controls, p = 0.1333) despite elevated low-density lipoprotein (LDL) cholesterol levels.

Conclusion: The current study indicates that individuals with GHRD have normal or improved levels of cardiovascular disease risk factors as compared to their relatives.

Funding: This study was funded in part by NIH/NIA grants P01 AG034906 to V.D.L.

Graphical Abstract



eTOC blurb

Guevara-Aguirre et al, evaluated the cardiovascular disease risk factors in individuals with Laron syndrome and their relatives to identify the effects of decreased growth hormone signaling on cardiovascular disease in humans. The study reports that decreased GH signaling has neutral to protective effects on cardiovascular disease risk factors.

Introduction

Human subjects with generalized growth hormone insensitivity due to growth hormone receptor deficiency /Laron syndrome, display IGF-1 deficiency, a very low incidence of insulin resistance, diabetes, cancer, as well as delayed age-related cognitive decline [1–4]. IGF-I deficiency has been associated with increased CVD in humans [5,6] yet, in mice, it is associated with an extended lifespan, raising the possibility that the limited role of atherosclerosis in mouse longevity could hide the detrimental effects of GHR/IGF-I deficiency. Interestingly, it has also been shown that cardiac-specific disruption of the GHR leads to IGF-1 deficiency but does not affect cardiac structure and function in adult male mice, although, it does affect glucose homeostasis[7].In general, arteries and the heart are known for their sensitivity to circulating IGF-I, and its deficiency has been associated with vascular derangements leading to atherosclerosis and impairment of cardiac mass and functionality[8–11]. However, subjects with excess levels of circulating GH i.e. patients diagnosed with acromegaly, hence with high IGF-1 serum concentrations, also display arterial endothelial cell abnormalities that eventually lead to CV disorders and death [12]. Growth hormone receptor deficiency (GHRD)/Laron syndrome (LS) subjects do not appear to display the 40% life-span extension observed in Growth hormone receptor knockout ($GHR^{-/-}$) mice, although they may live longer than relatives [1,13] raising the possibility that increased incidence of cardiovascular disease (CVD) may prevent in humans the major longevity extension observed in mice.

Here we tested many markers of CVD in two phases: one in a cohort of 30 individuals (GHRD=16, control relatives =14), brought to USC, in Los Angeles for assessment, and the second including additional individuals tested in Ecuador (where the subjects live) for a total of 44 individuals (GHRD=21, control relatives =23) (Figure 1). The aim was to evaluate cardiovascular risk factors and markers using state-of-the-art non-invasive techniques.

Results

Los Angeles Study

Clinical assessment of blood markers in GHRD subjects compared to control relatives showed higher total cholesterol (196.9 ± 30.79 vs 175.3 ± 26.3, p = 0.0493), higher LDL cholesterol (123.5 ± 24.33 vs 100.7 ± 27.18, p = 0.0245), lower glucose (86.81 ± 11.41 vs 103.9 ± 24.52, p = 0.0184), lower insulin (3.51 ± 1.37 vs 8.16 ± 3.13, p < 0.0001), and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR; 0.8 ± 0.3 vs 2.2 ± 1.0, p<0.0001) among GHRD subjects as compared to control relatives (Supplementary Table 1). GHRD showed higher counts for white blood cells, absolute neutrophils, and absolute eosinophils (Supplementary Table 2).

Carotid intima-media thickness (CIMT) is useful to assess the extent of carotid atherosclerotic vascular disease[14]. GHRD subjects had lower CIMT values as compared to their control relatives for both left (0.49 ± 0.10 vs 0.60 ± 0.11, p = 0.0106) and right (0.45 ± 0.11 vs 62 ± 0.15, p = 0.0015) common carotid artery (Table 1).

Flow-mediated dilation (FMD) is a non-invasive measure of cardiovascular risk[15]. GHRD subjects had a smaller baseline brachial artery diameter as compared to control relatives (2.98 ± 0.50 vs 3.64 ± 0.75, p = 0.0101) but a similar % FMD (5.66 ± 3.66 vs 3.65 ± 3.14, p = 0.1336) (Table 1).

Electrocardiography (ECG) showed an increased heart rate (68 ± 7 vs 57 ± 10, p = 0.0023) and shorter intervals (PR segment and QRS segment) in GHRD individuals as compared to that in the control group (Table 2). A much higher percentage of control relatives showed minor symptoms of cardiac risk, mainly sinus bradycardia as compared to GHRD subjects (85.71% vs 31.25%, p=0.0039 **, Fisher's exact test), although it was determined to be not clinically relevant by the cardiologist (Table 2).

Ecuador Study

A larger follow-up study on an overlapping cohort of individuals (23 out of 30 participants (76.6%) of the participants from the Los Angeles study was carried out in Ecuador, where a significant portion of the world's GHRD/LS population resides. This study included 21 GHRD subjects and 23 control relatives (44 total) (Figure 1).

Blood pressure was significantly lower in the GHRD group as compared to the control group (systolic: 112.1±18.6 vs. 124.5±16.5mmHg, p=0.025; diastolic: 66.3±7.8 vs. 72.5±12.3mmHg, p=0.057), with similar findings observed during measurements repeated before applanation tonometry (systolic: 115.8±17.5 vs. 126.3±15.4 mmHg, p=0.038; diastolic: 65.6±6.2 vs. 76.3 ±8.5 mmHg, p<.0001) (Table 3).

Pulse wave velocity is a measurement of arterial stiffness and a predictor of CVD risk[16]. During applanation tonometry (n=21 LS vs. 23 control relatives), GHRD subjects displayed a shorter estimated travelled distance but had similar carotid-femoral pulse wave velocity (PWV, 7.2 ±1.6 vs. 8.1 ±2.1 m/sec, p=0.109) and central pulse pressure (40.3±14.6 vs. 37.9±11.4 mmHg, p=0.529) as compared to that in control relatives. Also, GHRD subjects had higher augmented pressure (14.1±6.9 vs. 10.6±5.5%, p=0.07) as well as augmentation index (33.6±7 vs. 26.7±8.8 %, p=0.001). A higher augmentation index was observed in GHRD subjects even when normalized to a heart rate of 75 (Table 3).

At electrocardiography, both GHRD subjects and the control group displayed normal sinus rhythm, and no subjects displayed major conduction delays (Table 3). During echocardiography (n=14 GHRD vs. 11 control subjects), GHRD subjects were found to have smaller cardiac dimensions than controls, even when parameters were corrected for body surface area. These measurements included left ventricular mass (42.6±12.0 vs. 51.6±11.6 g/m^2, p=0.07), and end-diastolic volume (32.9 ±5.0 vs. 42.5 ±6.4 mL/m^2, p=0.0003). Neither GHRD nor control subjects reached the international standard threshold for left ventricular hypertrophy[17]. Systolic function parameters were normal in both GHRD subjects

and controls, and no participants displayed a left ventricular ejection fraction of less than 55%. However, GHRD subjects showed a higher % ejection fraction as compared to that in the control group (70.3±5.7 vs. 64.5±4.7%, p=0.014). Similar findings were observed in diastolic function parameters. 5 controls but only 2 GHRD subjects had abnormal left ventricular relaxation and normal average filling pressure values (E/E' 8±3 vs. 9±2, p=0.823). No major valve disease was noticed in either group. Intima-media thickness was lower in the GHRD subjects as compared to that in the control group (0.3±0.1 vs. 0.5±0.2 mm, p=0.001). GHRD subjects displayed a non-significant trend for a major reduction in atherosclerotic plaques compared to controls with at least one plaque present in 7% of GHRD subjects vs. 36% of controls (p = 0.1333) (Table 3), notwithstanding the higher values of LDL cholesterol in GHRD versus control subjects (140.6 ±33.9 vs. 110.5 ±26.5 mg/dL, p=0.013).

GHRD and control subjects displayed a significant positive correlation of PWV with age and systolic BP. Only the control group showed a significant positive correlation of PWV with glucose (control- spearman's correlation r = 0.52, p= 0.0485; GHRD- spearman's correlation r = 0.24, p= 0.41). The control group also showed a correlation of IMT with age (control- spearman's correlation r = 0.82, p= 0.0032) and glucose level (control- spearman's correlation r = 0.72, p= 0.0159), while the GHRD group does not (Supplementary Table 3).

Discussion

Our CVD risk factor assessment of an Ecuadorian cohort of GHRD subjects is the most comprehensive in the literature both for the number of subjects tested and the range of tests. In general, CV abnormalities observed in conditions of excess GH and IGF-I concentrations, as those seen in patients with acromegaly have been studied extensively[18]. On the contrary, there are only a few reports on CVD in subjects with GH/IGF-I deficiencies [19,20]. Moreover, there are no studies on the parameters of arterial stiffness in these subjects. Early reports suggested an increased incidence of CVD-related mortality in individuals with hypopituitarism, hypothesized to be caused by GH deficiency[21]. However, later studies have shown that individuals with untreated severe isolated GH deficiency while showing increased levels of cholesterol and obesity do not show any carotid wall thickness or premature atherosclerosis, raising the possibility that the therapy regimen that includes steroid hormone substitution could be to reason behind increased CVD mortality among individuals suffering from hypopituitarism[22]. Our previous study on the cause of death in the LS/GHRD population in Ecuador indicated that individuals with GHRD have an unusually high rate of alcohol and accident-related deaths as well as convulsive disorders whereas cancer- or diabetes-related deaths or incidence were very low. Notably, our earlier studies show a comparable incidence of CVD (cardiac disease + stroke) related deaths for GHRDs as compared to those in their control relatives (30% vs 33%) [1] although it is difficult to determine whether this may be influenced by the overreporting of cardiac disease as a cause of death, when another clear cause of death is not observed.

Our study was performed with advanced echocardiography and state-of-the-art testing for non-invasive investigation of arterial stiffness (i.e., PWV). We found smaller cardiac dimensions in GHRD subjects than that in controls even after normalizing for the body

size. Similar PWV was observed in GHRD individuals and the control group, along with a very low prevalence of subjects with carotid plaques as compared to the control group. Age-related changes in PWV and IMT were similar in subjects with GHRD and controls. Lower SBP, possibly inducing less arterial damage, might explain the trend for fewer arterial plaques in individuals affected with GHRD.

In summary, compared to control subjects, GHRD/LS subjects, display enhanced insulin sensitivity, lower blood pressure, no rhythm disturbances, smaller cardiac dimensions, similar PWV, lower CIMT, higher eGFR, lower creatinine, and a trend for a strong reduction in carotid atherosclerotic plaques despite elevated LDL cholesterol levels. Several studies have shown that BMI and not height is associated with increased CIMT[23,24]. In our study, BMI is matched in the two groups, and in fact, the GHRD group has a slightly higher BMI as compared to control individuals (31 ±6.1 vs 30.1 ±8.1) and higher frequency of individuals with BMI>30 (57% vs 52%). Hence, CIMT does not appear to require normalization for height.

Here, based on methodologies to diagnose macroscopic organ damage associated with aging and CV risk factors, we find that GHRDs have normal or reduced levels of CVD risk factors or markers in comparison to their age and sex-matched control relatives living under comparable environmental circumstances. In fact, the lower BP in addition to the strong tendency for reduced atheroma plaques despite high LDL cholesterol as well as enhanced insulin sensitivity in GHRDs, suggests a protective rather than neutral effect of GHRD on CV health.

Limitations of the study

One limitation of the study is that GHRD subjects are much smaller in size than controls, although this was largely addressed by normalizations. Another limitation is the lack of genotyping for the control population, although the likely presence of some GHRD heterozygosity is expected to strengthen further the results presented. We have not corrected for multiple hypothesis testing to keep the statistical analysis simple. It is possible that after such correction several of the marginally significant improvements seen in the GHRD group may no longer be statistically significant. However, since we are reporting GHRD to have neutral to positive effects on CVD risk, such changes would not affect our general conclusions.

STAR METHODS

RESOURCE AVAILABILITY

Lead contact—Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Valter D. Longo (vlongo@usc.edu).

Materials availability—This study did not generate new unique reagents.

Data and code availability—The patient data reported in this study cannot be deposited in a public repository because of patient privacy concerns. To request access to deidentified patient data, please contact Prof. Valter D. Longo (vlongo@usc.edu). Deidentified data

reported in this paper will be shared by the lead contact upon reasonable request and subject to approval by Institutional Review Board at the University of Southern California, Los Angeles, USA. This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

Human studies—Participants information on sex, age, and gender was self-reported. Information on race and socioeconomic status was not collected.

Phase 1: USC Keck Hospital, Los Angeles data collection - For the preliminary study 14 GHRD subjects and 16 control relatives were invited to the USC Keck Hospital in Los Angeles for assessment of complete blood count (CBC), serum parameters, common carotid artery intima-media thickness (CIMT), and flow-mediated dilation (FMD) of the brachial artery measurement.

Phase 2: Ecuador data collection - For a more detailed assessment we collected data from a random group of adult GHRD subjects (n=21) with GHRD from a historical Ecuadorian sample, and with homozygosity for the ss180 mutation [1] and performed a series of CV examinations. Studies included clinical history and physical examination, carotid applanation tonometry, electrocardiography, echocardiography, carotid ultrasonography, and routine laboratory tests. Depending on logistical variables, subjects were tested either at the Instituto de Endocrinología IEMYR in Quito, or at outpatient medical offices installed in the inland cities of Piñas and Balsas in the Southern province of El Oro in Ecuador. As in previous studies, age- and sex-matched LS relatives (n=23) (ss180/WT or WT/WT), living under the same contextual conditions were included as controls. Electrocardiography, echocardiography, carotid ultrasonography, and laboratory tests were only performed on subjects who were able to travel to Quito (25 out of 44). The participants in this cohort included 23 subjects (out of 30) previously studied at USC-Keck in Los Angeles and 21 new participants.

Study approval—The Study was approved by the Institutional Review Board at University of Southern California, Los Angeles, USA, and Ethics Committee of the Institute IEMYR, Quito, Ecuador. All participants provided written informed consent.

Rodent studies—None

METHOD DETAILS

High-Resolution B-mode ultrasound carotid artery images for carotid intima-media-thickness were acquired with a Mindray M5 ultrasound imager using a linear array 7.5 MHz transducer. Baseline and reactive hyperemia brachial artery diameters were measured at baseline and at 60 seconds after cuff inflation. Values are expressed as mean ± SEM. Student’s paired t-tests were used to assess differences between GHRD and Control values.

Carotid artery ultrasound image acquisition: High resolution B mode ultrasound carotid artery images for carotid artery intima-media thickness (CIMT) measurement were acquired with a Mindray M5 ultrasound imager using a linear array 7.5 MHz transducer. The electrocardiogram (ECG) and ultrasound images were simultaneously recorded. Subjects were placed supine and positioned in a 45° molded head block to present the optimal angle for ultrasound examination. Using B mode, the common carotid artery (CCA) was imaged in cross-section and the scanhead moved laterally until the jugular vein and the CCA were stacked with the former above the latter. In this position, the central image line passes along the common diameter of both vessels. The scanhead was then rotated around the central image line 90° maintaining the jugular vein stacked above the CCA while obtaining a longitudinal view of both vessels. In this longitudinal view, the CCA far wall is horizontal. The proximal portion of the carotid bulb was included in all images as an anatomical reference point for standardization of CIMT measurements. Stacking the jugular vein and the CCA determines a repeatable probe angle that allows the same portion of the wall to be imaged at each examination. This leads to further standardization of image acquisition and processing which in turn decreases measurement variability [25]. The minimum gain necessary for clear visualization of structures was used. Images were acquired from the carotid bulb and internal carotid artery, but the emphasis of ultrasound imaging was on the distal centimeter of the CCA because least variability occurs in this area[26]. The far wall was used for statistical purposes since the measurement of near wall thickness is less accurate [27]. Each individual's baseline image was used as a guide to match the vascular and surrounding soft tissue structures of the follow-up examinations. This is a direct visual aid method for reproducing transducer angulation designed for repeat image acquisition for longitudinal studies. These techniques provide a high degree of standardization for image acquisition and processing, resulting in a significant reduction in measurement variability between scans; inter- and intra-sonographer coefficients of variation (CVs) are less than 3%. Even in multicenter studies with multiple acquisition sites, the methodology is highly stable and reproducible with low variability, less than 3% CV [28–30]. To assure the security of data, each ultrasound examination was duplicated and processed images were electronically stored.

The physical examination consisted of measurements of height (wall-mounted stadiometer), weight (standard scale), waist and hip circumference (metric tape), bicipital, tricipital, subscapular, and supra-iliac skinfolds (millimetric calliper). Blood pressure (BP) was determined according to international guidelines. Briefly, after having the subject rest for at least 5 minutes in a quiet room under a stable and comfortable temperature, the measurement was taken with an automated, validated device (Microlife BP3MS1-2D, Microlife Corporation, Berneck, Switzerland), and the mean of three consecutive BP measures was recorded. A second set of BP measurements were recorded during the pulse wave analysis to obtain real-time peripheral BP values and performing the test while assessing central BP parameters [31].

Following a standardized protocol and using a validated device (SphygmoCor CPV system, AtCorMedical, Sydney, Australia), recordings of carotid-femoral pulse wave velocity (PWV) and pulse wave analysis were obtained by carotid applanation tonometry. Carotid-femoral PWV was calculated by dividing traveled distance by transit time (PWV=distance/

time), with both parameters measured on the right side according to the previous recommendation that measurement on the right side is more robust compared to left [32]. Travelled distance was estimated by multiplying the direct distance between the carotid and the femoral arterial pulse by 0.80. The distance was measured via an upside-down infantometer, as generally recommended [33]. Pulse wave transit time was calculated as the time difference between the feet of the carotid and femoral arterial waveforms, gated to ECG. Pulse wave analysis was performed by compressing the right radial artery with the tip of the tonometer at the site of maximal pulsation, thereby generating the corresponding central waveform. Aortic systolic and diastolic BP, pulse pressure, augmented pressure and augmentation index were estimated using a validated transfer function [33].

A resting 12 lead electrocardiogram was recorded before PWV assessment using a standard electrocardiograph apparatus. Heart rate and exclusion of rhythm disturbances or signs of left ventricular hypertrophy were determined. Echocardiography was performed at the Universidad San Francisco de Quito (USFQ) by an experienced cardiologist using a GE Vivid T8 echocardiograph apparatus. Measurements were obtained according to standard recommendations [17]. Carotid ultrasound was performed with the same ultrasound machine, and according to international standards. Maximal intima-media thickness (IMT) was determined, and the presence and degree of atherosclerotic plaques were also evaluated. Blood tests including measurement of circulating lipids, creatinine, urea, and uric acid were also performed.

QUANTIFICATION AND STATISTICAL ANALYSIS

No statistical methods were used to predetermine sample size. Group allocation was not randomized, and investigators were not blinded to allocation during experiments. Investigators were blinded during data analysis and outcome assessments. Statistical analysis was performed using GraphPad Prism 9.4 (GraphPad Software). In all analyses, $P<0.05$ was considered statistically significant, and the significance of P values was annotated as in GraphPad (≥0.05 (NS), 0.01–0.05 (*), 0.001–0.01 (**), 0.0001–0.001 (***), <0.0001 (****)) Continuous variables are presented as the mean ±SD, and categorical variables as absolute frequencies and percentages. Statistically significant differences between the groups were identified using an unpaired t-test. Categorical variables were compared using Fishers' exact test. Spearman's correlation analyses were used to determine the association of PWV and IMT with age, systolic BP, blood glucose, and total cholesterol in both study groups. HOMA-IR was calculated using the following formula: HOMA-IR = (insulin(mU/L) × glucose (mg/dL)) / 405.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

Graphical abstract created in Biorender.com.

References

1. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng C-W, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, et al. (2011). Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans. Science Translational Medicine 3, 70ra13–70ra13. doi:10.1126/scitranslmed.3001845.
2. Bartke A, Sun LY, and Longo V (2013). Somatotropic Signaling: Trade-Offs Between Growth, Reproductive Development, and Longevity. Physiological Reviews 93, 571–598. 10.1152/physrev.00006.2012. [PubMed: 23589828]
3. Nashiro K, Guevara-Aguirre J, Braskie MN, Hafzalla GW, Velasco R, Balasubramanian P, Wei M, Thompson PM, Mather M, Nelson MD, et al. (2017). Brain Structure and Function Associated with Younger Adults in Growth Hormone Receptor-Deficient Humans. The Journal of Neuroscience 37, 1696–1707. 10.1523/jneurosci.1929-16.2016. [PubMed: 28073935]
4. Guevara-Aguirre J, Rosenbloom AL, Balasubramanian P, Teran E, Guevara-Aguirre M, Guevara C, Procel P, Alfaras I, De Cabo R, Di Biase S, et al. (2015). GH Receptor Deficiency in Ecuadorian Adults Is Associated With Obesity and Enhanced Insulin Sensitivity. The Journal of Clinical Endocrinology & Metabolism 100, 2589–2596. 10.1210/jc.2015-1678. [PubMed: 25985182]
5. Juul A, Scheike T, Davidsen M, Gyllenborg J, and Jørgensen T (2002). Low Serum Insulin-Like Growth Factor I Is Associated With Increased Risk of Ischemic Heart Disease. Circulation 106, 939–944. doi:10.1161/01.CIR.0000027563.44593.CC. [PubMed: 12186797]
6. Laughlin GA, Barrett-Connor E, Criqui MH, and Kritz-Silverstein D (2004). The Prospective Association of Serum Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-1 Levels with All Cause and Cardiovascular Disease Mortality in Older Adults: The Rancho Bernardo Study. The Journal of Clinical Endocrinology & Metabolism 89, 114–120. 10.1210/jc.2003-030967. [PubMed: 14715837]
7. Jara A, Liu X, Sim D, Benner CM, Duran-Ortiz S, Qian Y, List EO, Berryman DE, Kim JK, and Kopchick JJ (2016). Cardiac-Specific Disruption of GH Receptor Alters Glucose Homeostasis While Maintaining Normal Cardiac Performance in Adult Male Mice. Endocrinology 157, 1929–1941. 10.1210/en.2015-1686. [PubMed: 27035649]
8. Aguirre GA, González-Guerra JL, Espinosa L, and Castilla-Cortazar I (2018). Insulin-Like Growth Factor 1 in the Cardiovascular System. In Reviews of Physiology, Biochemistry and Pharmacology, Vol. 175, Nilius B, de Tombe P, Gudermann T, Jahn R, and Lill R, eds. (Springer International Publishing), pp. 1–45. 10.1007/112_2017_8. [PubMed: 29294200]
9. Jing Z, Hou X, Wang Y, Yang G, Wang B, Tian X, Zhao S, and Wang Y (2015). Association between insulin-like growth factor-1 and cardiovascular disease risk: Evidence from a meta-analysis. International Journal of Cardiology 198, 1–5. 10.1016/uicard.2015.06.114. [PubMed: 26143182]
10. Jara A, and Kopchick JJ (2016). Young at Heart. Endocrinology 157, 44–45. 10.1210/en.2015-1977. [PubMed: 26717472]
11. Lombardi G, Di Somma C, Grasso LFS, Savanelli MC, Colao A, and Pivonello R (2012). The cardiovascular system in growth hormone excess and growth hormone deficiency. Journal of Endocrinological Investigation 35, 1021–1029. 10.3275/8717. [PubMed: 23143695]
12. Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, and Giustina A (2018). A Consensus Statement on acromegaly therapeutic outcomes. Nature Reviews Endocrinology 14, 552–561. 10.1038/s41574-018-0058-5.
13. Coschigano KT, Clemmons D, Bellush LL, and Kopchick JJ (2000). Assessment of Growth Parameters and Life Span of GHR/BP Gene-Disrupted Mice*. Endocrinology 141, 2608–2613. 10.1210/endo.141.7.7586. [PubMed: 10875265]
14. Devine PJ, Carlson DW, and Taylor AJ (2006). Clinical value of carotid intima-media thickness testing. Journal of Nuclear Cardiology 13, 710–718. 10.1016/j.nuclcard.2006.07.007. [PubMed: 16945751]
15. Anderson TJ (2007). Prognostic Significance of Brachial Flow-Mediated Vasodilation. Circulation 115, 2373–2375. doi:10.1161/CIRCULATIONAHA.107.697045. [PubMed: 17485590]

16. Safar ME, Henry O, and Meaume S (2002). Aortic Pulse Wave Velocity: An Independent Marker of Cardiovascular Risk. The American Journal of Geriatric Cardiology 11, 295–304. 10.1111/i.1076-7460.2002.00695.X. [PubMed: 12214167]

17. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. (2015). Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography 28, 1–39.e14. 10.1016/i.echo.2014.10.003. [PubMed: 25559473]

18. Clayton RN (2003). Cardiovascular Function in Acromegaly. Endocrine Reviews 24, 272–277. 10.1210/er.2003-0009. [PubMed: 12788799]

19. Feinberg MS, Scheinowitz M, and Laron Z (2000). Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron Syndrome). The American Journal of Cardiology 85, 209–213. 10.1016/S00Q2-9149(99)00642-6. [PubMed: 10955379]

20. Feinberg MS, Scheinowitz M, and Laron Z (2003). Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age. American Heart Journal 145, 549–553. 10.1067/mhi.2003.175. [PubMed: 12660681]

21. Bülow B, Hagmar L, Eskilsson J, and Erfurth EM (2000). Hypopituitary Females Have a High Incidence of Cardiovascular Morbidity and an Increased Prevalence of Cardiovascular Risk Factors1. The Journal of Clinical Endocrinology & Metabolism 85, 574–584. 10.1210/jcem.85.2.6346. [PubMed: 10690858]

22. Menezes Oliveira JL, Marques-Santos C, Barreto-Filho JA, Ximenes Filho R, de Oliveira Britto A.V.o., Oliveira Souza A.H.n., Prado CM, Pereira Oliveira CR, Pereira RMC, de Almeida Ribeiro Vicente T.b., et al. (2006). Lack of Evidence of Premature Atherosclerosis in Untreated Severe Isolated Growth Hormone (GH) Deficiency due to a GH-Releasing Hormone Receptor Mutation. The Journal of Clinical Endocrinology & Metabolism 91, 2093–2099. 10.1210/jc.2005-2571. [PubMed: 16522693]

23. Shimizu Y, Nakazato M, Sekita T, Kadota K, Arima K, Yamasaki H, Goto H, Shirahama S, Takamura N, Aoyagi K, and Maeda T (2013). Relationship between adult height and body weight and risk of carotid atherosclerosis assessed in terms of carotid intima-media thickness: The Nagasaki Islands study. Journal of Physiological Anthropology 32, 19. 10.1186/1880-6805-32-19. [PubMed: 24180493]

24. Ebrahim S, Papacosta O, Whincup P, Wannamethee G, Walker M, Nicolaides AN, Dhanjil S, Griffin M, Belcaro G, Rumley A, and Lowe GDO (1999). Carotid Plaque, Intima Media Thickness, Cardiovascular Risk Factors, and Prevalent Cardiovascular Disease in Men and Women. Stroke 30, 841–850. 10.1161/01.STR.30.4.841. [PubMed: 10187889]

25. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C.-r., Liu C.-h., and Azen SP (1998). The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events. Annals of Internal Medicine 128, 262–269. 10.7326/0003-4819-128-4-199802150-00002. [PubMed: 9471928]

26. O'Leary DH, Bryan FA, Goodison MW, Rifkin MD, Gramiak R, Ball M, Bond MG, Dunn RA, Goldberg BB, and Toole JF (1987). Measurement variability of carotid atherosclerosis: real-time (B-mode) ultrasonography and angiography. Stroke 18, 1011–1017. doi:10.1161/01.STR.18.6.1011. [PubMed: 3317999]

27. Wendelhag I, Gustavsson T, Suurküla M, Berglund G, and Wikstrand J (1991). Ultrasound measurement of wall thickness in the carotid artery: fundamental principles and description of a computerized analysing system. Clin Physiol 11, 565–577. 10.1111/j.1475-097x.l991.tb00676.x. [PubMed: 1769190]

28. Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, Schouten J, Mickelberg K, Li Y, Hodis HN, and Team, f.t.A.S. (2005). Carotid artery intima–media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 19, 927–933. 10.1097/01.aids.0000171406.53737.f9. [PubMed: 15905673]

29. Currier JS, Kendall MA, Henry WK, Alston-Smith B, Torriani FJ, Tebas P, Li Y, and Hodis HN (2007). Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS (London, England) 21, 1137–1145. 10.1097/qad.0b013e32811ebf79. [PubMed: 17502724]

30. Kaplan RC, Kingsley LA, Gange SJ, Benning L, Jacobson LP, Lazar J, Anastos K, Tien PC, Sharrett AR, and Hodis HN (2008). Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 22, 1615–1624. 10.1097/QAD.0b013e328300581d. [PubMed: 18670221]

31. Canepa M, Artom N, Ameri P, Carbone F, Montecucco F, Ghigliotti G, Brunelli, Dallegri F, Pende A, and Pisciotta L (2018). Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia. International Journal of Cardiology 255, 215–220. 10.1016/j.ijcard.2017.12.051. [PubMed: 29290422]

32. Bossuyt J, Van De Velde S, Azermai M, Vermeersch SJ, De Backer TL, Devos DG, Heyse C, Filipovsky J, Segers P, and Van Bortel LM (2013). Noninvasive assessment of carotid-femoral pulse wave velocity: the influence of body side and body contours. J Hypertens 31, 946–951. 10.1097/HJH.0b013e328360275d. [PubMed: 23511340]

33. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FUS, Protogerou AD, et al. (2012). Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. Journal of Hypertension 30, 445–448. 10.1097/HJH.0b013e32834fa8b0. [PubMed: 22278144]

Context and Significance statement

Growth hormone receptor deficiency (GHRD)/Laron syndrome, which results in disrupted GH signaling and lower IGF-1 and insulin, is associated with protection against diabetes, cancer, and age-related cognitive decline. However, the impact of decreased GH and IGF-1 signaling on the risk of cardiovascular disease is unclear with studies suggesting both increased and decreased risk.

Guevara-Aguirre et al, performed state of the art comprehensive evaluation of the cardiovascular function and risk factors in GHRD subjects and their relatives to establish the role of GH signaling in cardiovascular health. They report that individuals with GHRD have a normal or improved levels of cardiovascular disease risk factors as compared to their relatives living in the same geographical locations and similar lifestyle.

Highlights

- Individuals with Laron syndrome/GHRD have low growth hormone signaling.
- GHRD individuals have smaller cardiac dimensions.
- GHRD individuals have normal or improved levels of cardiovascular disease risk factors.



Figure 1.
CONSORT style diagram showing the patient groups and the tests performed.

Table 1.

Cardiac assessment of patients with GHRD and controls (USC-cohort).

	Control (mean±SD)	n	GHRD (mean±SD)	n	p-value	Significance
Common carotid artery intima-media thickness (CIMT)-left (mm)	0.60 ± 0.11	12	0.49 ± 0.10	16	0.0106	*
Common carotid artery intima-media thickness (CIMT)-right (mm)	0.62 ± 0.15	12	0.45 ± 0.11	16	0.0015	**
Baseline branchial artery diameter (mm)	3.6 ± 0.8	13	3.0 ± 0.5	15	0.0101	*
% Flow mediated dilation	3.7 ± 3.1	13	5.7 ± 3.7	15	0.1336	ns

Table 2.

Cardiac assessment of patients with GHRD and controls (USC-cohort) using electrocardiogram.

Electrocardiogram	Control (mean±SD)	n	GHRD (mean±SD)	n	p-value	Significance
ECG	28.57% abnormal	14	18.75% abnormal	16	0.6746	ns
Sinus rhythm	85.71% abnormal	14	31.25% abnormal	16	0.0039	**
Heart rate	57 ± 10	14	68 ± 7	16	0.0023	**
PR segment, msec	162 ± 27	14	138 ± 22	16	0.0113	*
QRS segment, msec	78 ± 10	14	65 ± 6	16	0.0002	***
QTc segment, msec	407 ± 16	14	416 ± 20	16	0.2115	ns

Table 3.

Characteristics of patients with GHRD and controls at the time of cardiovascular assessment (Ecuador).

Clinical	Control (mean±SD)	n	GHRD (mean±SD)	n	p-value	Significance
Age, years	51.7 ±13.1	23	46.5 ±13.0	21	0.193	ns
Male gender	26%	23	24%	21	0.862	ns
Height, cm	153.2 ±7	23	118.5 ±9.5	21	<0.0001	****
Weight, kg	70.4 ±18.4	23	43.9 ±11.7	21	<0.0001	****
Body mass index (BMI)	30.1 ±8.1	23	31 ±6.1	21	0.687	ns
BMI≥30	52%	23	57%	21	0.74	ns
Body surface area (BSA), m^2	1.7 ±0.2	23	1.1 ±0.2	21	<0.0001	****
Head circumference, cm	54.5 ±1.8	23	51.8 ±1.8	21	<0.0001	****
Waist circumference, cm	95.1 ±15.9	23	83.5 ±10.8	21	0.009	***
Hip circumference, cm	108 ±16.5	23	103.4 ±23.7	21	0.463	ns
Waist to hip ratio	0.9 ±0.1	23	0.8 ±0.1	21	0.018	*
Pulse rate, bpm	73.2 ±13.6	23	76.5 ±7.2	21	0.334	ns
Clinical systolic blood pressure (SBP)	124.5 ±16.5	23	112.1 ±18.6	21	0.025	*
Clinical diastolic blood pressure (DBP)	72.5 ±12.3	23	66.3 ±7.8	21	0.057	ns
Carotid applanation tonometry						
Test SBP, mmHg	126.3 ±15.4	23	115.8 ±17.5	21	0.038	*
Test DBP, mmHg	76.3 ±8.5	23	65.6 ±6.2	21	<0.0001	****
PWV direct carotid-femoral distance x 0.80, mm	468.3 ±36.4	23	387.3 ±35.7	21	<0.0001	****
PWV, m/sec	8.1 ±2.1	23	7.2 ±1.6	21	0.109	ns
Aortic pulse pressure mmHg	37.9 ±11.4	23	40.3 ±14.6	21	0.529	ns
Aortic augmented pressure mmHg	10.6 ±5.5	23	14.1 ±6.9	21	0.07	ns
Augmentation index, %	26.7 ±8.8	23	33.6 ±7	21	0.001	**
Augmentation index @75 bpm, %	25.3 ±9	23	33.3 ±6	21	0.001	**
Electrocardiogram						
Sinus rhythm, %	100%	15	100%	14		
Heart rate	68 ±11	15	77 ±9	14	0.038	*
PR segment, msec	160 ±20	15	144 ±19	14	0.04	*
QRS segment, msec	90 ±12	15	73 ±7	14	0.0001	***
QTc segment, msec	419 ±20	15	414 ±17	14	0.529	ns
Echocardiography						
Aortic root diameter, mm	28.9 ±3.1	11	23.4 ±3.7	14	0.001	***
Interventricular septum diastolic thickness, mm	6.8 ±1.3	11	5.1 ±1.3	14	0.003	**
Left ventricular end-diastolic (LVED) diameter	45.9 ±4.6	11	40.1 ±2.9	14	0.001	***
Posterior wall diastolic thickness, mm	5.9 ±1.5	11	4.6 ±1.1	14	0.021	*
Left ventricular end-systolic (LVES) diameter	24.7 ±7	11	24.6 ±2.7	14	0.967	ns
Left ventricle (LV) mass	89.2 ±29.8	11	49.0 ±9.9	14	<0.0001	****

Clinical	Control (mean±SD)	n	GHRD (mean±SD)	n	p-value	Significance
LV mass index, g/m^2	51.6 ±11.6	11	42.6 ±12.0	14	0.07	ns
LV hypertrophy	0%	11	0%	14		
E/A ratio	1.2 ±0.5	11	1.6 ±0.6	14	0.089	ns
Deceleration time,	206.7 ±72	11	150 ±47.5	14	0.027	*
Em lateral, cm/sec	12.9 ±4	11	14.8 ±4.8	14	0.295	ns
Em septal, cm/sec	9.5 ±2.9	11	11.5 ±3.5	14	0.129	ns
Em average, cm/sec	11.2 ±3.2	11	13.2 ±3.9	14	0.186	ns
E/Em ratio	9±2	11	8±3	14	0.823	ns
Left atrial (LA) diameter	34.8 ±7.1	11	31.6 ±3.2	14	0.138	ns
LA area biplane, cm^2	17.3 ±3	11	12.2 ±2.3	14	<0.0001	****
LA volume biplane, mL	49.7 ±15	11	29.5 ±8.7	14	0.0003	***
LA volume index, mL/m^2	28.8 ±6.7	11	25.1 ±7.1	14	0.1966	ns
LVED volume biplane, mL	72.5 ±14.8	11	38.9 ±8.3	14	<0.0001	****
LVES volume biplane, mL	27.1 ±5.8	11	17.5 ±8.5	14	0.004	**
LVED volume index, mL/m^2	42.5 ±6.4	11	32.9 ±5.0	14	0.0003	***
LVES volume index, mL/m^2	16.1 ±3.9	11	14.4 ±5.3	14	0.392	ns
LV ejection fraction biplane, %	64.5 ±4.7	11	70.3 ±5.7	14	0.014	*
Right ventricle (RV) basal diastolic diameter	38.7 ±5.1	11	31 ±3.4	14	0.001	***
RV mid diastolic diameter, mm	30.5 ±6.7	11	24.7 ±2.6	14	0.006	**
RV length, mm	74.1 ±7.6	11	60.2 ±6.2	14	<0.0001	****
RV diastolic wall thickness, mm	6.6 ±1.1	11	5.2 ±1.2	14	0.006	**
RV s' (systolic excursion velocity)	15.5 ±2.8	11	13.4 ±1.8	14	0.033	*
Tricuspid valve regurgitation pressure gradient, mmHg	28.4 ±10.9	11	31.1 ±12.2	14	0.571	ns
Tricuspid annular plane systolic excursion (TAPSE)	23.8 ±2.6	11	19.9 ±2.2	14	0.001	***
Inferior vena cava diameter	18.1 ±3.9	11	13.8 ±2	14	0.001	***
Carotid ultrasound	N=11		N=14			
Intima media thickness, mm	0.5 ±0.2	11	0.3 ±0.1	14	0.001	***
Carotid plaque (at least one)	36%	11	7%	14	0.1333	ns
Laboratory tests						
Urea, mg/dL	28.8 ±7.9	15	30.7 ±5.5	14	0.452	ns
Creatinine, mg/dL	0.8 ±0.1	15	0.7 ±0.1	14	0.032	*
Total cholesterol, mg/dL	193.3 ±35.7	15	214.6 ±40.4	14	0.142	ns
HDL cholesterol, mg/dL	54 ±11.3	15	52 ±12.1	14	0.649	ns
LDL cholesterol, mg/dL	110.5 ±26.5	15	140.6 ±33.9	14	0.013	*
Triglycerides, mg/dL	138.3 ±78.3	15	111.2 ±42.2	14	0.262	ns
Uric acid, mg/dL	5 ±1	15	4.7 ±0.9	14	0.396	ns
Fasting glucose, mg/dL	110.3 ±24.9	15	90.7 ±9.8	14	0.002	**
Glucose 120 min, mg/dL	119.6 ±53.1	15	98 ±19.6	14	0.164	ns

Clinical	Control (mean±SD)	n	GHRD (mean±SD)	n	p-value	Significance
C reactive protein,	4.9 ±5.1	15	6.8 ±3.9	14	0.278	ns
Medications						
Antihypertensive	17.40%	23	23.80%	21	0.598	ns
Lipid-lowering	4.40%	23	9.50%	21	0.496	ns
Antiplatelets	0%	23	4.80%	21	0.3	ns

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Bacterial and virus strains		
Biological samples		
Chemicals, peptides, and recombinant proteins		
Critical commercial assays		
Deposited data		
Experimental models: Cell lines		
Experimental models: Organisms/strains		
Oligonucleotides		
Recombinant DNA		
Software and algorithms		
GraphPad Prism 9.4	GraphPad Software	https://www.graphpad.com/

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Other		